News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Kowa Pharmaceuticals America Announces the Divestment of CAMBIA(TM) and PRO-571



12/14/2009 9:41:18 AM

MONTGOMERY, Ala.--(BUSINESS WIRE)--Kowa Pharmaceuticals America, Inc. (KPA), a privately-held specialty pharmaceutical company headquartered in Montgomery, AL, announces the divestment of its unique franchise of diclofenac products, including CAMBIA™ (diclofenac potassium for oral solution), recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute migraine headache pain, and PRO-571, a product development candidate for the potential treatment of acute pain.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES